Pharma Reaserch Prod Co Ltd (214450) — Cash Flow-to-Debt Ratio
Pharma Reaserch Prod Co Ltd (214450) has a Cash Flow-to-Debt Ratio of 0.19x as of December 2025, meaning its operating cash flow of ₩61.53 Billion could theoretically repay 0% of its total liabilities (₩320.01 Billion) in one year. See Pharma Reaserch Prod Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pharma Reaserch Prod Co Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Pharma Reaserch Prod Co Ltd across 11 annual periods. For the full cash flow conversion analysis, see Pharma Reaserch Prod Co Ltd cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Pharma Reaserch Prod Co Ltd (2015–2025)
Year-by-year debt coverage analysis for Pharma Reaserch Prod Co Ltd. Check 214450 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.57x | ₩183.16 Billion | ₩320.01 Billion | ▲ +17.1% |
| 2024 | 0.49x | ₩139.88 Billion | ₩286.26 Billion | ▼ -45.0% |
| 2023 | 0.89x | ₩64.95 Billion | ₩73.09 Billion | ▲ +101.3% |
| 2022 | 0.44x | ₩59.40 Billion | ₩134.55 Billion | ▼ -17.4% |
| 2021 | 0.53x | ₩65.30 Billion | ₩122.20 Billion | ▲ +22.7% |
| 2020 | 0.44x | ₩32.39 Billion | ₩74.41 Billion | ▲ +37.4% |
| 2019 | 0.32x | ₩19.27 Billion | ₩60.85 Billion | ▲ +268.6% |
| 2018 | 0.09x | ₩5.20 Billion | ₩60.56 Billion | ▼ -89.8% |
| 2017 | 0.84x | ₩8.56 Billion | ₩10.18 Billion | ▼ -20.8% |
| 2016 | 1.06x | ₩8.16 Billion | ₩7.69 Billion | ▼ -16.8% |
| 2015 | 1.28x | ₩16.02 Billion | ₩12.56 Billion | — |